Analyst Price Targets — VRCA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 27, 2026 11:57 am | — | Lake Street | $9.00 | $5.00 | TheFly | Verrica Pharmaceuticals initiated with a Buy at Lake Street |
| December 18, 2025 8:41 am | Kemp Dolliver | Loop Capital Markets | $17.00 | $8.05 | StreetInsider | Brookline Capital Markets Upgrades Verrica Pharmaceuticals (VRCA) to Buy |
| May 14, 2024 9:35 am | Glen Santangelo | Jefferies | $12.00 | $11.28 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies |
| May 14, 2024 6:51 am | Oren Livnat | H.C. Wainwright | $14.00 | $9.56 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $14 at H.C. Wainwright |
| July 25, 2023 1:03 pm | Serge Belanger | Needham | $10.00 | $5.32 | Benzinga | Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval |
Latest News for VRCA
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company…
Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028.
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRCA.
U.S. House Trading
No House trades found for VRCA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.